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Chemoresistance is one of the leading causes of cancer‐related deaths in the United States. Triple negative breast cancer (TNBC), a
subtype lacking the known breast cancer receptors used for targeted therapy, is reliant on chemotherapy as the standard of care. The
Adenomatous Polyposis Coli (APC) tumor suppressor is mutated or hypermethylated in 70% of sporadic breast cancers with
APC‐deficient tumors resembling the TNBC subtype. Using mammary tumor cells from the ApcMin/+ mouse model crossed to
the Polyoma middle T antigen (PyMT) transgenic model, we previously showed that APC loss decreased sensitivity to doxorubicin
(DOX). Understanding the molecular basis for chemoresistance is essential for the advancement of novel therapeutic approaches to
ultimately improve patient outcomes. Resistance can be caused via different methods, but here we focus on the DNA repair response
with DOX treatment. We show that MMTV‐PyMT;ApcMin/+ cells have decreased DNA damage following 24 hour DOX treatment
compared to MMTV‐PyMT;Apc+/+ cells. This decreased damage is first observed 24 hours post‐treatment and continues throughout
24 hours of drug recovery. Activation of DNA damage response pathways (ATM, Chk1, and Chk2) are decreased at 24 hours
DOX‐treatment in MMTV‐PyMT;ApcMin/+ cells compared to control cells, but show activation at earlier time points. Using
inhibitors that target DNA damage repair kinases (ATM, ATR, and DNA‐PK), we showed that ATM and DNA‐PK inhibition
increased DOX‐induced apoptosis in the MMTV‐PyMT;ApcMin/+ cells. In the current work, we demonstrated that APC loss imparts
resistance through decreased DNA damage response, which can be attenuated through DNA repair inhibition, suggesting the
potential clinical use of DNA repair inhibitions as combination therapy.
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Introduction
Breast cancer is one of the most commonly diagnosed cancers among
US women. There are several subtypes of breast cancer, each with a unique
molecular signature, prognosis, and treatment regimen [1]. Triple negative
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breast cancer (TNBC) is characterized by its lack of the three most fre-
quently upregulated receptors in breast cancer: estrogen (ER), proges-
terone (PR), and human epidermal growth factor 2 (HER2) receptors
[2]. As an aggressive subtype of breast cancer, TNBC has a poor prognosis
despite medical advances [2,3]. This is due to the limited targeted therapy
options for TNBC; therefore, chemotherapeutic agents are the standard of
care for these patients [3,4]. While tumors initially respond well to
chemotherapy, they often develop resistance, which is a major obstacle
in cancer therapy and is one of the leading causes of cancer‐related death
[5,6].
Previously, we have shown that the loss of the tumor suppressor Ade-
nomatous Polyposis Coli (APC) imparts chemoresistance in breast cancer
cells [7]. The APC tumor suppressor is lost in up to 70% of sporadic breast
cancers, either through mutation or hypermethylation [8–10]. APC‐
deficient tumors, specifically with promoter methylation, were shown to
correlate with ER and PR negative subtype of breast cancer, demonstrating
that APC‐deficient tumors have limited targeted therapy options, which
could contribute to their poorer prognosis [9]. Understanding how APC
loss affects response to chemoresistance is essential in improving patient
outcome. Using the ApcMin/+ mouse model, with a nonsense mutation
in one allele of Apc, we identified enhanced breast tumorigenesis in the
presence of the Polyoma middle T antigen (PyMT) oncogene [11]. Using
cells derived from this model, MMTV‐PyMT;ApcMin/+ cells, we have
demonstrated decreased sensitivity to doxorubicin (DOX) [7,12]. We have
previously shown that DOX resistance is mediated partially through acti-
vation of signal transducer and activator of transcription 3 (STAT3), but
how APC loss is affecting other chemoresistant mechanisms still requires
further investigation [12]. Understanding how APC loss can reduce sensi-
tivity will be essential in identifying combination therapies to overcome
this resistance.
Knowing how the chemotherapeutic agents work provides a first
clue into potential mechanisms by which tumor cells evade death by
chemotherapy. Many chemotherapeutic agents induce DNA damage
to cause apoptosis; however, cancer cells have developed mechanisms
to either repair damage or prevent damage from inducing apoptosis
[13]. Based on the damage incurred, the cell activates distinct repair
pathways, or if left unrepaired the damage can induce cell cycle arrest,
promoting senescence or apoptosis [13,14]. Damage can include inter‐
and intra‐strand DNA crosslinks, base damages, altered bases, stalled
replication forks, single stranded breaks (SSBs), or double stranded
breaks (DSBs). Due to the lethal nature of DSBs, many cancer thera-
peutics work by inducing such damage. DOX, a topoisomerase II (topo
II) inhibitor [15], is one of the most common single or combination
therapies for women with TNBC [6], and works through induction
of DSBs. DSB repair can be mediated through homologous recombina-
tion repair (HRR) or nonhomologous end joining (NHEJ). HRR
requires a sister chromatid to be used as a template to minimize errors
in the DNA, but this limits the occurrence of HRR, only taking place
in S and G2 phases of the cell cycle. NHEJ does not have such lim-
itations and occurs throughout the cell cycle. Both repair pathways are
mediated by the repair serine/threonine kinases: ataxia telangiectasia
mutated (ATM) or ataxia telangiectasia and Rad3 related (ATR), but
only NHEJ activates DNA‐dependent protein kinase (DNA‐PK).
Recent studies have shown that DNA damage repair pathways can be
enhanced in cancer cells providing a survival advantage after chemother-
apy [13]. For instance, cancer cells often contain mutations in repair
pathway proteins, including ATM, and additionally inhibiting these
repair kinases can restore sensitivity to irradiation [16]. Furthermore,
DNA repair proteins are increasingly mutated as cancer progresses mak-
ing these repair pathways ideal areas of therapeutic targets [17]. Herein,
we investigate the impact of APC loss on DNA damage response after
DOX treatment in breast cancer.
Materials and methods
Cells and drug treatment
MMTV‐PyMT;Apc+/+ and MMTV‐PyMT;ApcMin/+ cells were isolated
as previously described from primary mouse mammary tumors [11] and
grown in RPMI 1640 media supplemented with 10% fetal bovine serum,
1% penicillin/streptomycin, and 1:5000 plasmocin (Invivogen). MMTV‐
PyMT;ApcMin/+ cells, expressing one truncated and one WT allele of APC,
resemble the triple negative subtype of breast cancer cells (Supplemental
Figure 1) [11]. Cells were passaged using 0.25% trypsin/EDTA and main-
tained at 37 C with 5% CO2. Cells were plated and treated 24 hours later
with each chemotherapeutic agent or solvent control: doxorubicin
(500 nM, MP Biomedicals, LLC), etoposide (10 M, Sigma), paclitaxel
(2.5 M, Sigma), cisplatin (16 M, Sigma), VE‐821 (10 M, Selleckchem),
KU‐55955 (10 M, Selleckchem), or NU‐7441 (5 M, Tocris). Drug treat-
ments were performed for 24 hours unless otherwise indicated.
Immunoblot assays
Total protein lysates were isolated using a phosphatase inhibitor
enhanced lysis buffer (20 mM Tris‐HCl, 150 mM NaCl, 1% Triton‐X,
0.5% NP‐40, 50 mM NaF, 1 mM Na3VO4, 5 mM sodium pyrophos-
phate, 0.2 mM PMSF, 1x protease inhibitor cocktail (Fisher), and 1x
phosphatase inhibitor cocktail 2 (Sigma)). Protein was loaded onto
SDS‐PAGE gels for electrophoresis and transferred to Immobilon‐P mem-
brane (Millipore). Membranes were blocked for 1 hour at room tempera-
ture in 5% non‐fat dry milk in 1XTBS with 0.1% Tween (TBS‐T). Anti‐
phospho H2AX (1:1000, Cell Signaling), anti‐cleaved caspase 3 (1:1000,
Cell Signaling), anti‐phospho Chk1 Ser345 (1:500, Cell Signaling), anti‐
Total Chk1 (1:500, Abcam), anti‐phospho Chk2 Thr68 (1:500, Abcam),
anti‐Total Chk2 (1:500, Abcam), anti‐phospho ATM Ser1981 (1:500,
GeneTex), anti‐Total ATM (1:1000, Cell Signaling), anti‐phospho ATR
Thr1989 (1:1000, GeneTex), anti‐Total ATR (1:1000, Cell Signaling),
anti‐HER2 (1:1000; Cell Signaling), anti‐ER (1:1000, Santa Cruz),
anti‐PR (1:1000; Abcam) were used as primary antibodies. As loading
controls, blots were probed for anti‐‐Actin (1:25000, Sigma), anti‐
GAPDH (1:1000, Cell Signaling) or anti‐Tubulin (1:1000, Sigma) for
1 hour at room temperature followed by 1 hour in secondary antibody.
The phosphorylation of Chk1, Chk2, ATR, and ATM was normalized
to total protein over GAPDH, Actin, or Tubulin. yH2AX and CC3 were
normalized to Actin. Densitometry was performed using ImageJ Software.
Immunofluorescence
40,000 cells were plated on glass coverslips in a 12 well plate in tripli-
cate and 24 hours later cells were treated as described above. After treat-
ment, cells were fixed in 3.7% formaldehyde for 15 minutes and
permeabilized in 0.3% Triton X‐100 for 15 minutes. Antibodies were
diluted in blocking buffer that consisted of 0.2% non‐fat dry milk, 2%
Bovine Serum Albumin and 0.3% Triton X‐100 in phosphate buffered
saline (PBS). Primary anti‐phospho H2AX (1:650, Millipore) was applied
to cells for 1 hour at 37 C. Following washes in PBS, samples were incu-
bated in goat‐anti‐rabbit Alexa Fluor 488 (1:1000, Life Technologies) and
Alexa 555 conjugated Phalloidin (1:200, Life Technologies) to visualize F‐
actin. Slides were mounted with Fluoromount G with Hoescht (Sigma) to
label cell nuclei. The percentage of positive cells was determined for each
assay with at least 300 cells being counted per condition using the count-
ing feature on an Evos Xl core microscope. Each assay was run in triplicate
and repeated three times. Representative images were taken on Zeiss Axio
A1 Microscope with an AxioCam MRc digital camera.
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Alkaline comet assay
DNA damage was assessed using CometAssay Kit (Trevigen). Cells
were resuspended in ice‐cold 1X PBS to 1X105 cells/ml and mixed with
molten LMAgarose at a volume ratio of 1:5. The cell/agarose mixture
was spread evenly onto comet slides and then allowed to incubate at
4 C in the dark for 30 minutes. The slides were then placed in cold lysis
solution at 4 C overnight. Slides were incubated in Alkaline Unwinding
Solution pH > 13 (300 nM NaOH, 1 mM EDTA) for 1 hour at 4 C in
the dark, and then were electrophoresed at 1 Volt/cm at 300 mA for 45
minutes at 4 C. Slides were washed twice with dH20 for 5 minutes, once
with 70% ethanol for 5 minutes, and then dried at 37 C. SYBR‐Gold
Figure 1. Decreased DOX-induced DNA damage in APC-deficient cells. A) Protein levels of phosphorylated H2AX (yH2AX), a marker of DNA
damage, was measured in MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ cells following 24 hr treatment of chemotherapeutic agents, cisplatin
(CIS), doxorubicin (DOX), and paclitaxel (PTX). B) Quantification of western blots show that yH2AX was induced after DOX and PTX treatment in
MMTV-PyMT;Apc+/+ cells, but not in MMTV-PyMT;ApcMin/+ cells. In contrast CIS treatment induced equal damage in both cell lines. C)
Representative images of yH2AX immunofluorescence (IF) in DOX and PTX-treated MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells. White
arrows depict yH2AX positive cells, and the scale bar is 20 microns. D) Quantification of yH2AX IF images show an increased percentage of yH2AX in
DOX-treated MMTV-PyMT;Apc+/+ cells, which is reduced in DOX treated MMTV-PyMT;ApcMin/+ cells. Each experiment was repeated 3 times, at least
150 cells were counted per condition in each experiment. E) MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells were treated with DOX or PTX for
24 hours and DNA damage was assessed by the comet assay. The tail moment was measured and showed that DOX-treated MMTV-PyMT;Apc+/+ cells
have increased tail moment compared to solvent control. DOX-treated MMTV-PyMT;ApcMin/+ cells show no change compared to solvent control, and
were significantly decreased compared to the DOX-treated MMTV-PyMT;Apc+/+ cells. The data are shown as means SD; *P < 0.05 comparing MMTV-
PyMT;ApcMin/+ or MMTV-PyMT;Apc+/+ cells treated to solvent control and **P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+
cells.
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Staining Solution (1:10,000 in 10 mM Tris‐HCL pH 7.5, 1 mM EDTA;
Invitrogen) was used to stain the DNA for 30 minutes at room tempera-
ture in the dark. Images were captured using the Evos Xl core fluorescent
microscope and at least 50 cells were analyzed for each slide using
CometScore 2.0. Tail moment combines the amount of DNA in the tail
with distance of migration.
Statistical analysis
All values are reported as mean SD. Data from multiple treatment
groups were compared using a one‐way ANOVA with a post‐hoc Tukeys
t‐test or a Kruskal‐Wallis test.
Results
Decreased DNA damage in cells with low APC
DOX causes DSBs in the DNA resulting in activation of two DNA
repair pathways: NHEJ or HRR. One of the earliest events after DSBs
is the phosphorylation of Ser139 on histone 2AX (H2AX), a known mar-
ker of DNA damage. The phosphorylated protein is then referred to as
yH2AX. Following 24 hour treatment of chemotherapy drugs (DOX,
PTX, or CIS), MMTV‐PyMT;ApcMin/+ cells show decreased DNA dam-
age signaling as measured by yH2AX. The decrease in yH2AX suggests
decreased DNA damage is observed with APC loss following treatment
with DOX or PTX (Figure 1A and B). This decreased DNA damage
response was also seen by immunofluorescence where DOX treated
MMTV‐PyMT;ApcMin/+ cells showed a 40% decrease in the percent of
yH2AX positive cells compared to MMTV‐PyMT;Apc+/+ treated cells
(Figure 1C and D). The alkaline comet assay was performed to determine
whether the decreased yH2AX was due to decreased DNA damage follow-
ing DOX treatment. Measurement of the tail moment showed that DOX
treatment in the MMTV‐PyMT;Apc+/+ cells resulted in an increased tail
moment as expected. However, DOX‐treated MMTV‐PyMT;ApcMin/+ -
cells showed no change compared to the solvent control, and were signif-
icantly decreased compared to the DOX‐treated control cells (Figure 1E).
These data demonstrate that there is decreased DNA damage response fol-
lowing 24 hours of DOX treatment in MMTV‐PyMT;ApcMin/+ cells com-
pared to control. This decreased damage could be contributing to the
DOX resistance we previously reported in APC‐deficient cells [7].
Decreased DNA damage over time
To identify if this decreased DNA damage after 24 hours of DOX
treatment is due to reduced DNA damage response, we observed the
dynamics of yH2AX formation and loss following treatment and recovery.
Cells were treated with DOX for 6, 12, and 24 hours, with drug treatment
being removed at 24 hours. Fresh media was given, and protein was col-
lected at 6, 12, and 24 hours of recovery. In agreement with our initial
DNA damage data (Figure 1), yH2AX was not differentially detected in
the APC‐deficient cells compared to controls until 24 hours of DOX treat-
ment. This decrease in yH2AX levels continued throughout recovery (Fig-
ure 2A–F), demonstrating that the 24 hour timepoint is pivotal in
understanding the mechanism behind decreased DNA damage signaling
(Figure 2C). Cells were also treated with Etoposide (Etop), another topo
II inhibitor, to determine whether the damage response is DOX‐specific.
APC status did not alter the response to Etop until 12 hours of recovery
(Supplemental Figure 2E). Decreased DNA damage with APC loss is not
specific to DOX treatment.
Figure 2. Decreased DNA Damage Response after DOX treatment in APC-deficient cells. A-C) yH2AX protein levels were measured after 6, 12, or 24
hr treatment of DOX in MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells. After 6 (A) and 12 (B) hrs, treatment with DOX resulted in no change
in yH2AX in either cell line. C) After 24 hr treatment, DOX induced yH2AX in MMTV-PyMT;Apc+/+ cells, but not in MMTV-PyMT;ApcMin/+ cells.
D–F) Following 24 hr treatment, drug was removed and fresh media was added to MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells. Protein was
collected at 6, 12, or 24 hr post-recovery. After 6 hr recovery (D), DOX induced yH2AX in MMTV-PyMT;Apc+/+ cells, but not in MMTV-PyMT;
ApcMin/+ cells. E) After 12 hr recovery, DOX treated MMTV-PyMT;Apc+/+ cells had increased yH2AX protein levels. No DNA damage was measured in
MMTV-PyMT;ApcMin/+ cells treated with DOX. F) DOX treated MMTV-PyMT;Apc+/+ cells exhibited increased yH2AX levels following 24 hr recovery,
but no increase in yH2AX was observed in MMTV-PyMT;ApcMin/+ cells. *P < 0.05 comparing MMTV-PyMT;ApcMin/+ or MMTV-PyMT;Apc+/+ cells
treated to solvent control and **P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells.
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Decreased DNA damage repair signaling
DSBs are repaired via HRR and NHEJ through the PI3K related
kinases: ATM, ATR, and DNA‐PK. These kinases are responsible for
phosphorylating substrates for cell cycle arrest, checkpoint activation,
and repair pathways [18]. We first wanted to see whether DOX treatment
activated these kinases. Using the 24 hour treatment that we determined
from measuring yH2AX dynamics, we measured activation of ATR via
phosphorylation of ATR at Thr1989, and no change was observed with
APC loss and treatment of either DOX or PTX (Figure 3A). Activation
of ATM at 24 hrs post‐treatment was measured via expression of phospho-
rylated ATM at Ser1981. DOX treatment increased ATM activation in
MMTV‐PyMT;Apc+/+ cells, but no change was observed in the APC‐
deficient cells (Figure 3B). PTX treatment caused no activation of ATM
in either cell line (Figure 3B). To verify activation, we also assessed down-
stream targets of ATR and ATM, checkpoint kinase 1 (Chk1) and check-
point kinase 2 (Chk2), respectively. In contrast to the results of pATR
expression, Chk1 phosphorylation was observed in DOX‐treated
Figure 3. ATM-directed DNA damage repair in DOX treated cells. MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells were treated for 24 hrs
with DOX and PTX. Protein was isolated and western blots were used to determine expression of DNA damage repair components. A) No change was
observed in ATR phosphorylation (Thr1989) in either cell line following treatment. B) ATM activation was measured via phosphorylation of ATM
(Ser1981). Increased phosphorylation of ATM was observed in DOX treated MMTV-PyMT;Apc+/+ cells, but not in DOX treated MMTV-PyMT;
ApcMin/+ cells. C) DOX treated MMTV-PyMT;Apc+/+ cells expressed increased phosphorylation of Chk1 (Ser345), which is absent in MMTV-PyMT;
ApcMin/+ cells. D) Increased phosphorylation of Chk2 (Thr68) was observed in DOX treated MMTV-PyMT;Apc+/+ cells, with no change observed in
DOX treated MMTV-PyMT;ApcMin/+ cells. *P < 0.05 comparing MMTV-PyMT;ApcMin/+ or MMTV-PyMT;Apc+/+ cells treated to solvent control and
**P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells.
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MMTV‐PyMT;Apc+/+ cells but not in the MMTV‐PyMT;ApcMin/+ cells
(Figure 3C). In addition, phosphorylation of Chk2 was observed in
MMTV‐PyMT;Apc+/+ cells that were treated 24 hours with DOX, but
was absent in DOX‐treated MMTV‐PyMT;ApcMin/+ cells (Figure 3D).
PTX treatment resulted in no activation of Chk1 or Chk2 independent
of APC (Figure 3C and D). MMTV‐PyMT;ApcMin/+ cells show decreased
DNA damage following 24 hours DOX treatment and decreased activa-
tion of DNA repair at this timepoint. The above studies have investigated
a static time point of 24 hrs post treatment. While MMTV‐PyMT;
ApcMin/+ cells did not show ATM activation at 24 hours, a time course
study of 6, 12, and 24 hrs DOX treatment showed ATM activation in
MMTV‐PyMT;ApcMin/+ cells at 12 hrs post‐treatment (Supplemental Fig-
ure 3). Overall, there is reduced activation, and alteration of timing, of
DSB repair response in the MMTV‐PyMT;ApcMin/+ cells.
Inhibition of DNA repair pathways
Due to reduced DNA damage response with APC loss, we investigated
whether inhibiting DNA repair can prevent the APC‐induced DOX resis-
tance. DNA repair inhibitors, including those of ATR and ATM, have
been shown to increase sensitivity to radiotherapy and DNA‐damaging
chemotherapy in cells that are DNA repair deficient [15,19–21]. There-
fore, we used inhibitors of ATR and ATM, VE‐821 and KU55933,
respectively, to increase DOX‐induced apoptosis, as measured by cleaved
caspase 3 (CC3), in MMTV‐PyMT;ApcMin/+ cells compared to control
cells. We observed that ATM inhibition via KU55933 treatment increased
the DOX‐induced apoptosis in MMTV‐PyMT;ApcMin/+ cells compared to
control cells (Figure 4A), while inhibition of ATR via VE‐821 treatment
did not. Since DOX induces DSBs, which can be repaired by HRR or
NHEJ, and with NHEJ occurring throughout the cell cycle, we also inhib-
ited the NHEJ‐specific kinase DNA‐PK using NU7441 [22]. NU7441 in
combination with DOX increased DOX‐mediated apoptosis in MMTV‐
PyMT;ApcMin/+ cells compared to single treatment with DOX in
MMTV‐PyMT;ApcMin/+ cells (Figure 4B). Combination treatment in
MMTV‐PyMT;Apc+/+ cells augmented DOX‐mediated apoptosis demon-
strating the importance of NHEJ in preserving cancer cells during DOX
treatment.
Discussion
We previously demonstrated decreased sensitivity to DOX in MMTV‐
PyMT;ApcMin/+ cells compared to MMTV‐PyMT;Apc+/+ cells [7,12]. APC
has a role in base excision repair, and cancer cells have been shown to have
altered DNA repair pathways [23,24]. However, it is unclear whether
APC loss can enhance repair of the DSBs through NHEJ or HR repair.
We investigated how loss of APC affected DNA repair response to
DOX‐induced DSBs. We show that repair to DOX‐induced damage is
mediated through activation of ATM/Chk1/Chk2, which is absent with
APC loss. Targeting DSB repair pathways, HRR and NHEJ, showed pro-
mise at increasing DOX‐induced apoptosis in MMTV‐PyMT;ApcMin/+
cells.
Activation of ATM appears to play a more significant role in response
to DOX treatment. DOX treatment activated ATM, but not ATR, in
MMTV‐PyMT;Apc+/+ cells, whereas MMTV‐PyMT;ApcMin/+ cells
showed reduced activation of ATM, but not ATR. While this suggests
an importance of ATM activation in DOX response, activation of the
downstream proteins of ATM and ATR, Chk2 and Chk1 respectively,
both showed activation with DOX treatment in MMTV‐PyMT;Apc+/+-
cells, which was absent with APC loss. Phosphorylation of Chk1 has been
shown to be a better indicator of ATR activation, as opposed to the puni-
tive marker, pATR [25]. While there is crosstalk between ATM and ATR
kinase activity, the combination treatments of DOX with the ATM inhi-
bitor (KU55933) or the ATR inhibitor (VE‐821) on CC3 protein expres-
Figure 4. DNA repair inhibition increases DOX-induced apoptosis. A) Following 24 hr treatment with single agents or combination of DOX with
either VE-821 or KU55933, apoptosis was measured via cleaved caspase 3 (CC3). Treatment with VE-821 or KU55933 alone did not increase CC3
expression. Surprisingly, treatment with DOX and VE-821 decreased DOX-induced apoptosis in MMTV-PyMT;Apc+/+ cells. KU55933 treatment in
combination with DOX-induced apoptosis in MMTV-PyMT;ApcMin/+ cells. B) CC3 expression was measured following 24 hr treatment of DOX,
NU7441, or the combination in MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells. NU7441 alone did not induce CC3 expression. The
combination increased CC3 in MMTV-PyMT;Apc+/+ cells and increased the apoptotic response to DOX in MMTV-PyMT;ApcMin/+ cells. *P < 0.05
comparing MMTV-PyMT;ApcMin/+ or MMTV-PyMT;Apc+/+ cells treated to solvent control, **P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-
PyMT;Apc+/+ cells, and #P < 0.05 comparing the combination treatment versus the single agent (DOX).
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sion demonstrates the importance of ATM activation compared to ATR
activation [26,27]. Single treatment of KU55933 or VE‐821 did not
induce apoptosis in either cell line. In combination with DOX, only
KU55933 showed a synergistic effect at inducing apoptosis specifically
in the MMTV‐PyMT;ApcMin/+ cells. This supports the activation of
ATM being required for response to DOX treatment. The mechanism
by which APC loss results in decreased phosphorylation of ATM/Chk1/
Chk2 is unclear at this point.
Targeting NHEJ through inhibition of DNA‐PK also increased DOX‐
induced apoptosis. Due to NHEJ not needing a sister chromatid present
as a template for repair, NHEJ is more commonly used to repair DSBs by
ligating both ends of the break [22,28]. However, both NHEJ and HRR
appear important in inducing DOX‐mediated DNA repair with both
ATM and DNA‐PK inhibition re‐sensitizing cells to DOX treatment.
Future studies will investigate whether decreased damage is due to reduced
intracellular DOX concentration, increased DNA repair efficiency, or
decreased functionality of DOX.
Previously, we have shown that APC loss increased expression of the
ATP‐dependent efflux pump, multidrug resistance protein 1 (MDR1)
through STAT3 activation [12]. MDR1 expression is induced with
DOX exposure leading to resistance [29]. Therefore, it is possible that
there is reduced intracellular DOX resulting in decreased DNA damage.
STAT3 has also been shown to affect DNA repair, with low STAT3
decreasing ATM and ATR signaling through STAT3 transcriptional reg-
ulation of mediator of DNA damage checkpoint protein 1 (MDC1)
[30]. This would suggest that enhanced STAT3 could be increasing
ATM and ATR signaling resulting in enhanced repair. In addition,
APC is known to bind to topoisomerase IIa (topo IIa), a target of
DOX [31,32]. DOX functions through intercalation into the DNA and
inhibition of topo IIa, resulting in an accumulation of DSBs and induc-
tion of apoptosis. Whether this loss of interaction between APC and topo
IIa affects the efficacy of DOX is unknown. Lack of APC could alter topo
IIa activity, resulting in decreased DSBs with DOX exposure. Further
study will investigate these three mechanisms that could be causing this
decreased DNA damage at 24 hours in MMTV‐PyMT;ApcMin/+ cells.
The mechanism behind this reduced DNA damage response will be inves-
tigated to find how APC is imparting DOX resistance to access potential
combination therapies to restore DOX sensitivity. Targeting the DNA
repair pathways responsible for DSBs, NHEJ and HRR, can increase
DOX sensitivity. ATM activation is critical in DOX‐mediated repair,
more so than ATR or DNA‐PK, as demonstrated through inhibition of
ATM showing the most therapeutic potential. In vivo mouse studies will
be required to confirm this combination therapy.
Conclusion
Overall, we have shown that APC loss results in decreased DNA dam-
age response to DOX. This decreased damage contributes to the reduced
sensitivity to DOX that we previously have shown with APC loss [7,12].
Targeting ATM and DNA‐PK can increase DOX‐induced apoptosis. This
study suggests that targeting DNA repair pathways can be therapeutically
advantageous in DOX‐resistance breast cancer.
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